Previous studies demonstrated that ∼50% of acute myelogenous leukemia samples exhibit activation of the mitogen-activated protein kinase (MAPK) pathway and growth inhibition by MEK inhibitors. To extend these observations, we assessed MAPK pathway activation and effects of CI-1040 in normal and myelodysplastic (MDS) marrow.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Sep 1 2003|
- MEK inhibitors
ASJC Scopus subject areas